---
reference_id: "PMID:31560925"
title: "Aniridia and Axenfeld-Rieger Syndrome: Clinical presentations, molecular genetics and current/emerging therapies."
authors:
- Chrystal PW
- Walter MA
journal: Exp Eye Res
year: '2019'
doi: 10.1016/j.exer.2019.107815
content_type: abstract_only
---

# Aniridia and Axenfeld-Rieger Syndrome: Clinical presentations, molecular genetics and current/emerging therapies.
**Authors:** Chrystal PW, Walter MA
**Journal:** Exp Eye Res (2019)
**DOI:** [10.1016/j.exer.2019.107815](https://doi.org/10.1016/j.exer.2019.107815)

## Content

1. Exp Eye Res. 2019 Dec;189:107815. doi: 10.1016/j.exer.2019.107815. Epub 2019
Sep  24.

Aniridia and Axenfeld-Rieger Syndrome: Clinical presentations, molecular 
genetics and current/emerging therapies.

Chrystal PW(1), Walter MA(2).

Author information:
(1)Department of Medical Genetics, University of Alberta, Edmonton, AB, Canada.
(2)Department of Medical Genetics, University of Alberta, Edmonton, AB, Canada. 
Electronic address: mwalter@ualberta.ca.

Aniridia and Axenfeld-Rieger Syndrome are related, human ocular disorders that 
are typically inherited in an autosomal dominant manner. Both result from 
incorrect development of the eye and have, as their most serious consequences, 
elevated risk to develop the blinding condition glaucoma. This review will focus 
on describing the clinical presentations of Aniridia and Axenfeld-Rieger 
Syndrome as well as the molecular genetics and current and emerging therapies 
used to treat patients.

Crown Copyright Â© 2019. Published by Elsevier Ltd. All rights reserved.

DOI: 10.1016/j.exer.2019.107815
PMID: 31560925 [Indexed for MEDLINE]